Comprehensive Stock Comparison
Compare RAPT Therapeutics, Inc. (RAPT) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | REGN | Beta 0.58 vs RAPT's 0.78 |
| Dividends | REGN | 0.4% yield; 1-year raise streak; RAPT pays no meaningful dividend |
| Momentum (1Y) | RAPT | +5.4% vs REGN's +12.4% |
| Efficiency (ROA) | REGN | 11.1% ROA vs RAPT's -63.7%, ROIC 12.4% vs -155.7% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
RAPT Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies for cancer and inflammatory diseases. It generates no revenue yet as it's in clinical trials, with future income dependent on potential drug approvals and commercialization. The company's competitive advantage lies in its targeted CCR4 antagonist platform that selectively inhibits immune cell migration to diseased tissues.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
RAPT leads in 2 of 6 categories (Financial Metrics, Valuation Metrics). REGN leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Financial Metrics (TTM)
REGN and RAPT operate at a comparable scale, with $14.3B and $0 in trailing revenue.
| Metric | RAPTRAPT Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $14.3B |
| EBITDAEarnings before interest/tax | -$112M | $4.2B |
| Net IncomeAfter-tax profit | -$106M | $4.5B |
| Free Cash FlowCash after capex | -$87M | $3.2B |
| Gross MarginGross profit ÷ Revenue | — | +86.3% |
| Operating MarginEBIT ÷ Revenue | — | +25.7% |
| Net MarginNet income ÷ Revenue | — | +31.4% |
| FCF MarginFCF ÷ Revenue | — | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +82.9% | -2.5% |
Valuation Metrics
| Metric | RAPTRAPT Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $7.7B | $107.6B |
| Enterprise ValueMkt cap + debt − cash | $7.5B | $91.4B |
| Trailing P/EPrice ÷ TTM EPS | -2.27x | 18.84x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.25x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.98x |
| EV / EBITDAEnterprise value multiple | — | 21.64x |
| Price / SalesMarket cap ÷ Revenue | — | 7.50x |
| Price / BookPrice ÷ Book value/share | 1.56x | 2.72x |
| Price / FCFMarket cap ÷ FCF | — | 26.36x |
Profitability & Efficiency
REGN delivers a 14.4% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-70 for RAPT. RAPT carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to REGN's 0.09x. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs RAPT's 2/9, reflecting strong financial health.
| Metric | RAPTRAPT Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | -69.5% | +14.4% |
| ROA (TTM)Return on assets | -63.7% | +11.1% |
| ROICReturn on invested capital | -155.7% | +12.4% |
| ROCEReturn on capital employed | -79.3% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 7 |
| Debt / EquityFinancial leverage | 0.02x | 0.09x |
| Net DebtTotal debt minus cash | -$165M | -$16.2B |
| Cash & Equiv.Liquid assets | $170M | $18.9B |
| Total DebtShort + long-term debt | $4M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | — | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in REGN five years ago would be worth $16,977 today (with dividends reinvested), compared to $3,869 for RAPT. Over the past 12 months, RAPT leads with a +535.7% total return vs REGN's +12.4%. The 3-year compound annual growth rate (CAGR) favors REGN at 1.1% vs RAPT's -37.3% — a key indicator of consistent wealth creation.
| Metric | RAPTRAPT Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +82.0% | +0.8% |
| 1-Year ReturnPast 12 months | +535.7% | +12.4% |
| 3-Year ReturnCumulative with dividends | -75.4% | +3.4% |
| 5-Year ReturnCumulative with dividends | -61.3% | +69.8% |
| 10-Year ReturnCumulative with dividends | -44.3% | +104.7% |
| CAGR (3Y)Annualised 3-year return | -37.3% | +1.1% |
Risk & Volatility
REGN is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than RAPT's 0.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RAPT currently trades 100.0% from its 52-week high vs REGN's 95.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RAPTRAPT Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 0.58x |
| 52-Week HighHighest price in past year | $57.99 | $821.11 |
| 52-Week LowLowest price in past year | $5.67 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +100.0% | +95.2% |
| RSI (14)Momentum oscillator 0–100 | 79.2 | 49.1 |
| Avg Volume (50D)Average daily shares traded | 2.8M | 687K |
Analyst Outlook
Wall Street rates RAPT as "Hold" and REGN as "Buy". Consensus price targets imply 9.7% upside for REGN (target: $857) vs 3.5% for RAPT (target: $60). REGN is the only dividend payer here at 0.44% yield — a key consideration for income-focused portfolios.
| Metric | RAPTRAPT Therapeutics… | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $60.00 | $857.17 |
| # AnalystsCovering analysts | 15 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| RAPT Therapeutics, … (RAPT) | 100 | 39.83 | -60.2% |
| Regeneron Pharmaceu… (REGN) | 100 | 162.46 | +62.5% |
Regeneron Pharmaceu… (REGN) returned +70% over 5 years vs RAPT Therapeutics, … (RAPT)'s -61%. A $10,000 investment in REGN 5 years ago would be worth $16,977 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| RAPT Therapeutics, … (RAPT) | $0.00 | $0.00 | — |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| RAPT Therapeutics, … (RAPT) | -10.5% | -54.9% | -423.4% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| RAPT Therapeutics, … (RAPT) | -10.95 | -25.49 | -132.9% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 6Free Cash Flow — 5 Years
RAPT Therapeutics, Inc. generated $-83M FCF in 2024 (-35% vs 2021). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
RAPT vs REGN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RAPT or REGN a better buy right now?
Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 18.8x trailing P/E (17.3x forward), making it the more compelling value choice. Analysts rate Regeneron Pharmaceuticals, Inc. (REGN) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RAPT or REGN?
Over the past 5 years, Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of +69.8%, compared to -61.3% for RAPT Therapeutics, Inc. (RAPT). A $10,000 investment in REGN five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +104.7% versus RAPT's -44.3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RAPT or REGN?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc. (REGN) is the lower-risk stock at 0.58β versus RAPT Therapeutics, Inc.'s 0.78β — meaning RAPT is approximately 35% more volatile than REGN relative to the S&P 500. On balance sheet safety, RAPT Therapeutics, Inc. (RAPT) carries a lower debt/equity ratio of 2% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — RAPT or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus 0.0% for RAPT Therapeutics, Inc. — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus 0.0% for RAPT. At the gross margin level — before operating expenses — REGN leads at 86.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is RAPT or REGN more undervalued right now?
Analyst consensus price targets imply the most upside for REGN: 9.7% to $857.17.
06Which pays a better dividend — RAPT or REGN?
In this comparison, REGN (0.4% yield) pays a dividend. RAPT does not pay a meaningful dividend and should not be held primarily for income.
07Is RAPT or REGN better for a retirement portfolio?
For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc. (REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.58), +104.7% 10Y return). Both have compounded well over 10 years (REGN: +104.7%, RAPT: -44.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RAPT and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.